Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Peripheral blood lymphocytes (PBL) of gastric cancer patients in advanced stages showed lymphokine activated killer (LAK) activities comparable to those of healthy donors, suggesting potential applicability of LAK cells induced from PBL stimulated with recombinant interleukin-2 (rIL-2) in adoptive immunotherapy (AIT) for gastric cancer. In order to generate a large number of LAK cells from PBL, lymphocytes were cultured with both rIL-2 and phytohemagglutinin (PHA). In this culture, the numbers of cells increased to a greater extent than those in culture with rIL-2 alone but cytotoxic activity did not augment, thus suggesting that this procedure would not afford sufficient clinical effects. On the other hand, a large number of LAK cells with high anti-tumor activities were efficiently induced from spleen cells of the patients by culture of rIL-2; hence clinical usefulness of these LAK cells is anticipated. In regional lymph node lymphocytes (RLNL) cultured with rIL-2, the cytotoxic activities were lower than in those induced in PBL, and a characteristic increase of CD8 + CD11 + suppressor T cells was observed after incubation with rIL-2. Nevertheless, an increase of CD4 + 4B4 + helper inducer T cells was also observed in RLNL after the culture with rIL-2. Furthermore, high cytotoxic activities were induced in RLNL in some cases in which metastasis to the regional lymph nodes was not detected. When gastric cancer patients were pretreated with biological response modifiers (BRM), especially with Lentinan, LAK cells from PBL showed higher NK and LAK activities as compared with those of patients without BRM pretreatment.
 ...
PMID:Evaluation of basic procedures for adoptive immunotherapy for gastric cancer. 152 56

A 74-year-old man with advanced gastric cancer of Borrmann type III and liver metastasis was treated by combined administration of UFT (400 mg/day, p. o.), Mitomycin C (14 mg/body/4w., i.v.) and Lentinan (2 mg/w., i.v.). Five and half months after the therapy, endoscopic examination and ultrasonography showed the primary and liver-metastatic lesions had completely disappeared. Ten months after the therapy, total gastrectomy and intraoperative liver wedge biopsy were performed and complete disappearance of cancer cells was histologically confirmed. The total dose of UFT, MMC and LNT administered until the operation was 76.4 g, 42 mg and 74 mg, respectively. However, the patient eventually died of the recurrence of liver metastases three years after the initial immunochemotherapy.
 ...
PMID:[A case of advanced gastric cancer with liver metastasis completely responding to a combined immunochemotherapy with UFT, mitomycin C and lentinan]. 158 Jun 46

Specific antitumor effects of lymphokine activated lymphocytes obtained from tumor-bearing mice after intratumoral injection of IL-2 were studied. Furthermore, effects of preoperative endoscopic intratumoral injection combined IL-2 and Lentinan or OK-432 were clinically studied against gastric cancer. The results were as follows: After intratumoral consecutive injection of recombinant human IL-2 (rhIL-2), the splenocytes of these mice were cultured with rhIL-2 and the effector cells were obtained. 1) Adoptive transfer of the effector cells specifically diminished the size of the host tumor and prolonged the life span of the mice. 2) The analysis of the surface antigens indicated the Thy1.2, Thy1.2+ L3T4+ cells increased in the effector cells as the specific cytotoxicity of them were augmented. 3) Preoperative endoscopic intratumoral injection combined IL-2 and Lentinan or OK-432 induced immunocytes including antigen-presenting cells in the site of the gastric cancer, and increased the IL-2R and the LAK activity of PBL. This method was considered as effective as an adjuvant treatment of gastric cancer surgery as a in vivo sensitization.
 ...
PMID:[Intratumoral injection of biological response modifier (BRM)]. 194 92

Lentinan, a pure polysaccharide, augments many immune responses in vivo but not in vitro. Therefore reaction with any factor is thought to be required for triggering of immunopotentiation by lentinan. To clarify the role of complement in this effect, we investigated whether lentinan could activate alternative pathway of complement or not and the relation with the immunopotentiation in 13 gastric cancer patients. C3, C3a, C5 and C5a levels as parameters of complement activation and interleukin-2 producing activity as parameter of immunopotentiation were assayed before and immediately after intravenous injection of lentinan. Among these complement components, remarkable change was observed only in C3a level. C3a level elevated to more than 1000ng/ml from less than 300ng/ml. And according to the degree and continuation of the elevation, these patients were classified into 3 types-(1) every time little elevation, (2) first remarkable and thereafter little elevation and (3) continuous remarkable elevation. Such an elevated C3a level returned to the level before lentinan injection within one day. When C3a level elevated to more than 1000ng/ml, leukocyte counts of peripheral blood decreased significantly and interleukin-2 producing activity increased concomitantly. Thus, there was diversity in response to lentinan and complement activation was suggested to have contribution in immunopotentiation by lentinan.
 ...
PMID:[Diversity of complement activation by lentinan, an antitumor polysaccharide, in gastric cancer patients]. 201 26

Local injection of BRM (OK-432 or Lentinan) around the cancer lesions via endoscope was performed on 66 gastric cancer patients preoperatively, and the regional lymph node lymphocytes in the surgical specimens were examined on T-cell subset, production of IL-2, and responsiveness to IL-2. The results were as follows: 1) In the metastatic lymph nodes, proportions of T-lymphocyte subsets, production of IL-2 and responsiveness to IL-2 did not change after local administration of OK-432 or Lentinan. 2) In the non-metastatic lymph nodes, percentage of CD4+4B4+ cells were significantly increased and production of IL-2 was markedly augmented after local injection of OK-432. On the other hand, percentage of CD8+CD11- cells were significantly increased and production of IL-2 was markedly enhanced after the local injection of Lentinan. These data suggested that the antitumor response of the non-metastatic lymph node lymphocytes was augmented after the local injection of OK-432 or Lentinan.
 ...
PMID:[Analysis of immunological response of regional lymph node lymphocytes from patients with gastric cancer after endoscopic local injection of biological response modifier (BRM)]. 205 81

A 63-year-old female diagnosed as inoperable gastric cancer was treated with combination immunochemotherapy of Mitomycin C, Aclacinomycin A, SF-SP and Lentinan. In this case, the tumor directly invaded the pancreas and the peritoneal dissemination, metastasis to the para-aortic lymph nodes and Virchow's metastasis were identified. As the result of this therapy, the primary tumor was remarkably reduced in size. The subjective symptoms and the metastasis of the para-aortic lymph nodes and Virchow's metastasis disappeared. The side effect was only mild thrombocytopenia.
 ...
PMID:[A case report of advanced gastric cancer remarkably responding to mitomycin C, aclacinomycin A, SF-SP and lentinan combination therapy]. 210 85

A 59-year-old man with a gastric cancer underwent a laparotomy and was found to have an unresectable tumor that formed a large mass with metastatic lymph nodes around the aorta. He therefore was treated by a combined administration of Mitomycin C, FT-207, and Lentinan for 3 months. Remarkable tumor reduction was observed endoscopically, and a subtotal gastrectomy was performed. The immunochemotherapy then was resumed, and the patient has survived for 16 months despite the remnant lymph node metastases. A histological examination of the resected stomach revealed a marked degeneration of the tumor.
 ...
PMID:[An advanced gastric carcinoma which responded to combined administration of mitomycin C, FT-207, and lentinan immunochemotherapy]. 210 5

A 78-year-old female was diagnosed as having an early gastric cancer of II a (+II c) type with probable sm invasion by gastroscopic examination. Endoscopic polypectomy was carried out due to advanced age, severe ischemic heart disease, and refusal of surgical treatment. Most of the cancerous tissue were removed endoscopically, but biopsy specimens after polypectomy showed some tumor cells leaving at the excisional site. She was treated with local injection of OK-432 endoscopically, PSK orally, Tegafur rectally, and Lentinan intravenously. After about 7 months' treatments, biopsy specimens revealed no residual cancer cells. The total doses administered up to cure for cancer were 70 KE of OK-432, 141 g of PSK, 99 g of Tegafur, and 45 mg of Lentinan. The combination therapy with massive removal of cancer tissue by endoscopy, local injection of anti-cancer agent to residual cancerous lesion and systemic immunochemotherapy will be available and recommendable for poor risk patients with early gastric cancer.
 ...
PMID:[A case of early gastric cancer disappeared by endoscopic polypectomy and local injection of anti-cancer agent associated with systemic immunochemotherapy]. 226 22

Between 1977 and April in 1989, long-term survivors (over two years) by intra-arterial infusion chemotherapy in gastric cancer patients with liver metastases were examined. The materials were 5 patients (4 synchronous, 1 metachronous metastases) among 21 P0H (+) gastric cancers. The extent of liver metastases shows 1 H1 and 4 H2. Reduction surgery was performed in 4 H2 patients (2 S2 + 3, 1 S4, 1 S6) and postoperative intra-arterial infusion chemotherapy via the catheter in the common hepatic artery was done to control the residual liver metastases. Continuous intra-arterial infusion chemotherapy with the regimen of FML (5-FU, MMC, Lentinan) revealed 100% response rate (3 CR, 1 PR). In a patient with metachronous metastases, PR was obtained with MA (MMC, ADM) + one-shot intra-arterial infusion of LAK cells. Among 5 patients, one with synchronous metastases has survived 35 months, followed by a patient who died after 32 months and two patients who died after 27 months. A patient with metachronous metastases has survived for 24 months.
 ...
PMID:[Over two years survival of intra-arterial infusion chemotherapy in gastric cancer with liver metastases]. 250 30

We studied the effects of endoscopic intratumoral injection of Lentinan in 7 patients with advanced gastric cancer. Ten to 14 days before surgery, Lentinan at a dose of 3 mg was endoscopically injected into the cancer tissues. The effects of Lentinan injection were evaluated by immunohistochemical staining for lymphocyte subsets in the resected specimens and by the natural killer (NK) activity of peripheral blood lymphocytes before and after injection. The distribution of lymphocyte subsets in cancer tissues was compared with those of 7 patients with advanced gastric cancer without Lentinan injection (control group). The ratios of CD 8+ cells and CD 25+ cells to CD 3+ cells in cancer tissues were statistically higher in the group given Lentinan injection than in the control group. The NK activity of peripheral blood lymphocytes significantly increased from 16.0 +/- 4.6% before injection to 21.1 +/- 5.1% after injection. However, there were no changes in lymphocyte subsets during this period. There were no side effects caused by the Lentinan injection. We conclude that endoscopic intratumoral injection of Lentinan may enhance local and systemic immunity in patients with gastric cancer.
 ...
PMID:[Effects of endoscopic intratumoral injection of lentinan in patients with gastric cancer]. 325 78


1 2 3 4 Next >>